Ketogenic diets as an adjuvant therapy in glioblastoma (the KEATING trial): study protocol for a randomised pilot study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-11-28

AUTHORS

Kirsty J. Martin-McGill, Anthony G. Marson, Catrin Tudur Smith, Michael D. Jenkinson

ABSTRACT

BackgroundGlioblastoma is the commonest form of malignant brain tumour in adults, affecting 2–3 people per 100,000 per year. Despite current treatment options including surgical resection, radiotherapy and temozolomide chemotherapy, overall survival at 2 years is approximately 27%, with a median survival of 12–14 months. The ketogenic diet (KD) is postulated to work by simulating the metabolic response to fasting by promoting the utilisation of ketones as a primary energy source, and depriving the glycolytic pathways utilised by malignant glioma cells for growth. At present, there is no consensus as to which KD is preferable, with previous case series using different KDs, at different points in the treatment pathway. The aim of this randomised pilot study is to investigate protocol feasibility, tolerability and the impact on patient health and quality of life of two different KDs within an NHS setting. The results of this pilot study will inform which KD will be most deliverable and adhered to by patients in order to test for effectiveness in future trials.MethodsA prospective, non-blinded, randomised, pilot study will be undertaken in 12 patients with newly diagnosed glioblastoma treated by surgical resection. Patients will be randomised in a ratio of 1:1, using a permuted block randomisation method to one of two diets; the modified ketogenic diet and the medium chain triglyceride ketogenic diet. Primary data collection will take place 12 weeks after starting the diet and secondary data collection after 12 months. Feasibility will be assessed by retention and recruitment rates, ability to enrol patients prior to starting chemoradiotherapy, dietary compliance and adjustments, ketone levels, glucose levels and intervention time. Patient impact will be assessed through quality of life and food acceptability questionnaires, gastrointestinal side effects and changes to biochemical markers and anthropometric measures, assessed at regular intervals.DiscussionThe results of this pilot study will be used to inform the feasibility, methodological design and power calculations of future phase III clinical trials investigating the effectiveness of KD as an adjuvant therapy in the management of glioblastoma.Trial registrationISRCTN71665562 and NCT03075514. More... »

PAGES

67

References to SciGraph publications

  • 2013-10-25. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse in TRIALS
  • 2011-08-16. Questions asked and answered in pilot and feasibility randomized controlled trials in BMC MEDICAL RESEARCH METHODOLOGY
  • 2015-03-25. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature in CANCER & METABOLISM
  • 2015-03-11. The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer in NUTRITION & METABOLISM
  • 2016-05-09. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary in ACTA NEUROPATHOLOGICA
  • 2010-04-22. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report in NUTRITION & METABOLISM
  • 1993-04. Performance status assessment in cancer patients. An inter-observer variability study in BRITISH JOURNAL OF CANCER
  • 2013-05-24. Caloric restriction reduces edema and prolongs survival in a mouse glioma model in JOURNAL OF NEURO-ONCOLOGY
  • 2014-01-19. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme in JOURNAL OF NEURO-ONCOLOGY
  • 2013-08-20. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database in BMC MEDICAL RESEARCH METHODOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s40814-017-0209-9

    DOI

    http://dx.doi.org/10.1186/s40814-017-0209-9

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1093037521

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/29209515


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK", 
              "id": "http://www.grid.ac/institutes/grid.416928.0", 
              "name": [
                "Institute of Translational Medicine, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK", 
                "The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Martin-McGill", 
            "givenName": "Kirsty J.", 
            "id": "sg:person.011662512767.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011662512767.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK", 
              "id": "http://www.grid.ac/institutes/grid.416928.0", 
              "name": [
                "Institute of Translational Medicine, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK", 
                "The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Marson", 
            "givenName": "Anthony G.", 
            "id": "sg:person.01174075734.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174075734.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Biostatistics, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK", 
              "id": "http://www.grid.ac/institutes/grid.10025.36", 
              "name": [
                "Department of Biostatistics, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tudur Smith", 
            "givenName": "Catrin", 
            "id": "sg:person.01261374732.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261374732.97"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK", 
              "id": "http://www.grid.ac/institutes/grid.416928.0", 
              "name": [
                "Institute of Translational Medicine, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK", 
                "The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jenkinson", 
            "givenName": "Michael D.", 
            "id": "sg:person.0730365343.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730365343.68"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s11060-013-1154-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048542701", 
              "https://doi.org/10.1007/s11060-013-1154-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1745-6215-14-353", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015031168", 
              "https://doi.org/10.1186/1745-6215-14-353"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00401-016-1545-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021788062", 
              "https://doi.org/10.1007/s00401-016-1545-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1993.140", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042277183", 
              "https://doi.org/10.1038/bjc.1993.140"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-014-1362-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045712581", 
              "https://doi.org/10.1007/s11060-014-1362-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2288-11-117", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045260688", 
              "https://doi.org/10.1186/1471-2288-11-117"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1743-7075-7-33", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051847253", 
              "https://doi.org/10.1186/1743-7075-7-33"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40170-015-0129-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010394329", 
              "https://doi.org/10.1186/s40170-015-0129-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12986-015-0009-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014950931", 
              "https://doi.org/10.1186/s12986-015-0009-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2288-13-104", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021309233", 
              "https://doi.org/10.1186/1471-2288-13-104"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-11-28", 
        "datePublishedReg": "2017-11-28", 
        "description": "BackgroundGlioblastoma is the commonest form of malignant brain tumour in adults, affecting 2\u20133 people per 100,000 per year. Despite current treatment options including surgical resection, radiotherapy and temozolomide chemotherapy, overall survival at 2\u00a0years is approximately 27%, with a median survival of 12\u201314\u00a0months. The ketogenic diet (KD) is postulated to work by simulating the metabolic response to fasting by promoting the utilisation of ketones as a primary energy source, and depriving the glycolytic pathways utilised by malignant glioma cells for growth. At present, there is no consensus as to which KD is preferable, with previous case series using different KDs, at different points in the treatment pathway. The aim of this randomised pilot study is to investigate protocol feasibility, tolerability and the impact on patient health and quality of life of two different KDs within an NHS setting. The results of this pilot study will inform which KD will be most deliverable and adhered to by patients in order to test for effectiveness in future trials.MethodsA prospective, non-blinded, randomised, pilot study will be undertaken in 12 patients with newly diagnosed glioblastoma treated by surgical resection. Patients will be randomised in a ratio of 1:1, using a permuted block randomisation method to one of two diets; the modified ketogenic diet and the medium chain triglyceride ketogenic diet. Primary data collection will take place 12\u00a0weeks after starting the diet and secondary data collection after 12\u00a0months. Feasibility will be assessed by retention and recruitment rates, ability to enrol patients prior to starting chemoradiotherapy, dietary compliance and adjustments, ketone levels, glucose levels and intervention time. Patient impact will be assessed through quality of life and food acceptability questionnaires, gastrointestinal side effects and changes to biochemical markers and anthropometric measures, assessed at regular intervals.DiscussionThe results of this pilot study will be used to inform the feasibility, methodological design and power calculations of future phase III clinical trials investigating the effectiveness of KD as an adjuvant therapy in the management of glioblastoma.Trial registrationISRCTN71665562 and NCT03075514.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s40814-017-0209-9", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1053109", 
            "issn": [
              "2055-5784"
            ], 
            "name": "Pilot and Feasibility Studies", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "3"
          }
        ], 
        "keywords": [
          "different ketogenic diets", 
          "ketogenic diet", 
          "quality of life", 
          "pilot study", 
          "adjuvant therapy", 
          "surgical resection", 
          "future phase III clinical trials", 
          "effectiveness of KD", 
          "medium chain triglyceride ketogenic diet", 
          "phase III clinical trials", 
          "block randomisation method", 
          "previous case series", 
          "gastrointestinal side effects", 
          "current treatment options", 
          "malignant brain tumors", 
          "management of glioblastoma", 
          "malignant glioma cells", 
          "overall survival", 
          "median survival", 
          "dietary compliance", 
          "temozolomide chemotherapy", 
          "case series", 
          "treatment options", 
          "future trials", 
          "clinical trials", 
          "treatment pathways", 
          "ketone levels", 
          "glucose levels", 
          "brain tumors", 
          "side effects", 
          "anthropometric measures", 
          "acceptability questionnaire", 
          "biochemical markers", 
          "patients", 
          "patient health", 
          "randomisation method", 
          "patient impact", 
          "NHS settings", 
          "glioma cells", 
          "intervention time", 
          "place 12", 
          "metabolic response", 
          "common form", 
          "diet", 
          "glioblastoma", 
          "resection", 
          "protocol feasibility", 
          "therapy", 
          "trials", 
          "months", 
          "survival", 
          "regular intervals", 
          "power calculation", 
          "recruitment rates", 
          "glycolytic pathway", 
          "chemoradiotherapy", 
          "tolerability", 
          "data collection", 
          "chemotherapy", 
          "BackgroundGlioblastoma", 
          "radiotherapy", 
          "tumors", 
          "years", 
          "MethodsA", 
          "pathway", 
          "study", 
          "methodological design", 
          "weeks", 
          "adults", 
          "levels", 
          "markers", 
          "health", 
          "life", 
          "questionnaire", 
          "primary data collection", 
          "cells", 
          "options", 
          "aim", 
          "compliance", 
          "setting", 
          "response", 
          "feasibility", 
          "interval", 
          "adjustment", 
          "management", 
          "consensus", 
          "quality", 
          "protocol", 
          "effectiveness", 
          "measures", 
          "impact", 
          "rate", 
          "effect", 
          "people", 
          "changes", 
          "results", 
          "collection", 
          "retention", 
          "utilisation", 
          "ability", 
          "ratio", 
          "time", 
          "present", 
          "series", 
          "growth", 
          "different points", 
          "form", 
          "point", 
          "method", 
          "secondary data collection", 
          "source", 
          "design", 
          "order", 
          "primary energy source", 
          "ketones", 
          "energy sources", 
          "calculations"
        ], 
        "name": "Ketogenic diets as an adjuvant therapy in glioblastoma (the KEATING trial): study protocol for a randomised pilot study", 
        "pagination": "67", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1093037521"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s40814-017-0209-9"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "29209515"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s40814-017-0209-9", 
          "https://app.dimensions.ai/details/publication/pub.1093037521"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:03", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_751.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s40814-017-0209-9"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40814-017-0209-9'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40814-017-0209-9'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40814-017-0209-9'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40814-017-0209-9'


     

    This table displays all metadata directly associated to this object as RDF triples.

    242 TRIPLES      21 PREDICATES      152 URIs      134 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s40814-017-0209-9 schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author N5d5dec8b1f8947a59050754f20a5dabd
    4 schema:citation sg:pub.10.1007/s00401-016-1545-1
    5 sg:pub.10.1007/s11060-013-1154-y
    6 sg:pub.10.1007/s11060-014-1362-0
    7 sg:pub.10.1038/bjc.1993.140
    8 sg:pub.10.1186/1471-2288-11-117
    9 sg:pub.10.1186/1471-2288-13-104
    10 sg:pub.10.1186/1743-7075-7-33
    11 sg:pub.10.1186/1745-6215-14-353
    12 sg:pub.10.1186/s12986-015-0009-2
    13 sg:pub.10.1186/s40170-015-0129-1
    14 schema:datePublished 2017-11-28
    15 schema:datePublishedReg 2017-11-28
    16 schema:description BackgroundGlioblastoma is the commonest form of malignant brain tumour in adults, affecting 2–3 people per 100,000 per year. Despite current treatment options including surgical resection, radiotherapy and temozolomide chemotherapy, overall survival at 2 years is approximately 27%, with a median survival of 12–14 months. The ketogenic diet (KD) is postulated to work by simulating the metabolic response to fasting by promoting the utilisation of ketones as a primary energy source, and depriving the glycolytic pathways utilised by malignant glioma cells for growth. At present, there is no consensus as to which KD is preferable, with previous case series using different KDs, at different points in the treatment pathway. The aim of this randomised pilot study is to investigate protocol feasibility, tolerability and the impact on patient health and quality of life of two different KDs within an NHS setting. The results of this pilot study will inform which KD will be most deliverable and adhered to by patients in order to test for effectiveness in future trials.MethodsA prospective, non-blinded, randomised, pilot study will be undertaken in 12 patients with newly diagnosed glioblastoma treated by surgical resection. Patients will be randomised in a ratio of 1:1, using a permuted block randomisation method to one of two diets; the modified ketogenic diet and the medium chain triglyceride ketogenic diet. Primary data collection will take place 12 weeks after starting the diet and secondary data collection after 12 months. Feasibility will be assessed by retention and recruitment rates, ability to enrol patients prior to starting chemoradiotherapy, dietary compliance and adjustments, ketone levels, glucose levels and intervention time. Patient impact will be assessed through quality of life and food acceptability questionnaires, gastrointestinal side effects and changes to biochemical markers and anthropometric measures, assessed at regular intervals.DiscussionThe results of this pilot study will be used to inform the feasibility, methodological design and power calculations of future phase III clinical trials investigating the effectiveness of KD as an adjuvant therapy in the management of glioblastoma.Trial registrationISRCTN71665562 and NCT03075514.
    17 schema:genre article
    18 schema:isAccessibleForFree true
    19 schema:isPartOf N8ff3097254cf4d9bb97e2609e0dddb64
    20 Ne6fa3c000a5742a4988fc2fca39ea908
    21 sg:journal.1053109
    22 schema:keywords BackgroundGlioblastoma
    23 MethodsA
    24 NHS settings
    25 ability
    26 acceptability questionnaire
    27 adjustment
    28 adjuvant therapy
    29 adults
    30 aim
    31 anthropometric measures
    32 biochemical markers
    33 block randomisation method
    34 brain tumors
    35 calculations
    36 case series
    37 cells
    38 changes
    39 chemoradiotherapy
    40 chemotherapy
    41 clinical trials
    42 collection
    43 common form
    44 compliance
    45 consensus
    46 current treatment options
    47 data collection
    48 design
    49 diet
    50 dietary compliance
    51 different ketogenic diets
    52 different points
    53 effect
    54 effectiveness
    55 effectiveness of KD
    56 energy sources
    57 feasibility
    58 form
    59 future phase III clinical trials
    60 future trials
    61 gastrointestinal side effects
    62 glioblastoma
    63 glioma cells
    64 glucose levels
    65 glycolytic pathway
    66 growth
    67 health
    68 impact
    69 interval
    70 intervention time
    71 ketogenic diet
    72 ketone levels
    73 ketones
    74 levels
    75 life
    76 malignant brain tumors
    77 malignant glioma cells
    78 management
    79 management of glioblastoma
    80 markers
    81 measures
    82 median survival
    83 medium chain triglyceride ketogenic diet
    84 metabolic response
    85 method
    86 methodological design
    87 months
    88 options
    89 order
    90 overall survival
    91 pathway
    92 patient health
    93 patient impact
    94 patients
    95 people
    96 phase III clinical trials
    97 pilot study
    98 place 12
    99 point
    100 power calculation
    101 present
    102 previous case series
    103 primary data collection
    104 primary energy source
    105 protocol
    106 protocol feasibility
    107 quality
    108 quality of life
    109 questionnaire
    110 radiotherapy
    111 randomisation method
    112 rate
    113 ratio
    114 recruitment rates
    115 regular intervals
    116 resection
    117 response
    118 results
    119 retention
    120 secondary data collection
    121 series
    122 setting
    123 side effects
    124 source
    125 study
    126 surgical resection
    127 survival
    128 temozolomide chemotherapy
    129 therapy
    130 time
    131 tolerability
    132 treatment options
    133 treatment pathways
    134 trials
    135 tumors
    136 utilisation
    137 weeks
    138 years
    139 schema:name Ketogenic diets as an adjuvant therapy in glioblastoma (the KEATING trial): study protocol for a randomised pilot study
    140 schema:pagination 67
    141 schema:productId N03616df0ede04a75b9f1f43152294830
    142 N04fe26ab170a4000b7f2cafe91bba594
    143 Na5b2d6d6478c43b096450a5387745499
    144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1093037521
    145 https://doi.org/10.1186/s40814-017-0209-9
    146 schema:sdDatePublished 2022-11-24T21:03
    147 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    148 schema:sdPublisher Nccb85341f8874210a64f80877265ba06
    149 schema:url https://doi.org/10.1186/s40814-017-0209-9
    150 sgo:license sg:explorer/license/
    151 sgo:sdDataset articles
    152 rdf:type schema:ScholarlyArticle
    153 N03616df0ede04a75b9f1f43152294830 schema:name doi
    154 schema:value 10.1186/s40814-017-0209-9
    155 rdf:type schema:PropertyValue
    156 N04fe26ab170a4000b7f2cafe91bba594 schema:name pubmed_id
    157 schema:value 29209515
    158 rdf:type schema:PropertyValue
    159 N5d5dec8b1f8947a59050754f20a5dabd rdf:first sg:person.011662512767.33
    160 rdf:rest Neaa0d578190046ba8e823380d0094165
    161 N6e6ae06e486441bfa766dd605eeec5cf rdf:first sg:person.0730365343.68
    162 rdf:rest rdf:nil
    163 N8ff3097254cf4d9bb97e2609e0dddb64 schema:volumeNumber 3
    164 rdf:type schema:PublicationVolume
    165 Na5b2d6d6478c43b096450a5387745499 schema:name dimensions_id
    166 schema:value pub.1093037521
    167 rdf:type schema:PropertyValue
    168 Nc7fb44dcc15f4e99a1563ec8649d3b28 rdf:first sg:person.01261374732.97
    169 rdf:rest N6e6ae06e486441bfa766dd605eeec5cf
    170 Nccb85341f8874210a64f80877265ba06 schema:name Springer Nature - SN SciGraph project
    171 rdf:type schema:Organization
    172 Ne6fa3c000a5742a4988fc2fca39ea908 schema:issueNumber 1
    173 rdf:type schema:PublicationIssue
    174 Neaa0d578190046ba8e823380d0094165 rdf:first sg:person.01174075734.81
    175 rdf:rest Nc7fb44dcc15f4e99a1563ec8649d3b28
    176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    177 schema:name Medical and Health Sciences
    178 rdf:type schema:DefinedTerm
    179 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    180 schema:name Oncology and Carcinogenesis
    181 rdf:type schema:DefinedTerm
    182 sg:journal.1053109 schema:issn 2055-5784
    183 schema:name Pilot and Feasibility Studies
    184 schema:publisher Springer Nature
    185 rdf:type schema:Periodical
    186 sg:person.011662512767.33 schema:affiliation grid-institutes:grid.416928.0
    187 schema:familyName Martin-McGill
    188 schema:givenName Kirsty J.
    189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011662512767.33
    190 rdf:type schema:Person
    191 sg:person.01174075734.81 schema:affiliation grid-institutes:grid.416928.0
    192 schema:familyName Marson
    193 schema:givenName Anthony G.
    194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174075734.81
    195 rdf:type schema:Person
    196 sg:person.01261374732.97 schema:affiliation grid-institutes:grid.10025.36
    197 schema:familyName Tudur Smith
    198 schema:givenName Catrin
    199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261374732.97
    200 rdf:type schema:Person
    201 sg:person.0730365343.68 schema:affiliation grid-institutes:grid.416928.0
    202 schema:familyName Jenkinson
    203 schema:givenName Michael D.
    204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730365343.68
    205 rdf:type schema:Person
    206 sg:pub.10.1007/s00401-016-1545-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021788062
    207 https://doi.org/10.1007/s00401-016-1545-1
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1007/s11060-013-1154-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1048542701
    210 https://doi.org/10.1007/s11060-013-1154-y
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1007/s11060-014-1362-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045712581
    213 https://doi.org/10.1007/s11060-014-1362-0
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.1038/bjc.1993.140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042277183
    216 https://doi.org/10.1038/bjc.1993.140
    217 rdf:type schema:CreativeWork
    218 sg:pub.10.1186/1471-2288-11-117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045260688
    219 https://doi.org/10.1186/1471-2288-11-117
    220 rdf:type schema:CreativeWork
    221 sg:pub.10.1186/1471-2288-13-104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021309233
    222 https://doi.org/10.1186/1471-2288-13-104
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1186/1743-7075-7-33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051847253
    225 https://doi.org/10.1186/1743-7075-7-33
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1186/1745-6215-14-353 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015031168
    228 https://doi.org/10.1186/1745-6215-14-353
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1186/s12986-015-0009-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014950931
    231 https://doi.org/10.1186/s12986-015-0009-2
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1186/s40170-015-0129-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010394329
    234 https://doi.org/10.1186/s40170-015-0129-1
    235 rdf:type schema:CreativeWork
    236 grid-institutes:grid.10025.36 schema:alternateName Department of Biostatistics, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK
    237 schema:name Department of Biostatistics, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK
    238 rdf:type schema:Organization
    239 grid-institutes:grid.416928.0 schema:alternateName The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK
    240 schema:name Institute of Translational Medicine, University of Liverpool, Brownlow Hill, L69 3BX, Liverpool, UK
    241 The Walton Centre NHS Foundation Trust, Lower Lane, L9 7LJ, Liverpool, UK
    242 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...